PROPEL – Prospective Registry Of ParEnteraL prostanoids

Parenteral prostanoids are prescribed to patients diagnosed with pulmonary arterial hypertension (PAH) in order to maximize their exercise tolerance and to minimise their symptoms. PAH is a very rare disease with a prevalence of 1.5-2.6 patients per 100.000 population. It is therefore desirable to monitor and to assess the safety of patients treated by a specific treatment regularly and on a central level.

PAH is a disease of lung arterioles which is characterised by an increase of mean arterial pressure in the pulmonary artery (>25mm Hg at rest, >30mm Hg during exercise). It is also characterised by an increased pulmonary vascular resistance (>3 WU, Wood units).

Without adequate treatment, PAH progressively leads to heart failure and death. Median survival rate in untreated patients is around 2.8 years. Symptoms are non-specific, especially in early stages of the disease. Severity of symptoms considerably correlates with the prognosis of a given patient. The most common symptoms involve exertional dyspnoea, fatigue, chest pain and syncope.

PROPEL – the Prospective Registry Of ParEnteraL prostanoids – was focused on the collection of clinical data on PAH patients as well as data on therapeutic effects and safety of parenteral prostanoids.

Primary objective of the project:

• collection of clinical data on PH patients treated with parenteral prostanoids

Secondary objectives of the project:

• assessment of effectiveness of the chosen therapy,
• assessment of safety of the chosen therapy,
• analysis of survival in relation to monitored clinical factors,
• assessment of quality of life in PAH patients treated with parenteral prostanoids.

Other important information:

• Expert guarantors: Pavel Jansa, MD (General University Hospital in Prague, Czech Republic), Prof. Dr. Irene Lang (Medical University of Vienna, Austria), Prof. Jean-Luc Vachiery, MD (Erasme Hospital, Brussels, Belgium)
• Funding: United Therapeutics Europe, Ltd.
• Partners: specialized centres in six European countries (you can find more detailed information on the website of the PROPEL project)
• Brief overview of results: you can find more detailed information on the website of the PROPEL project